Description

Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its research and development efforts are underpinned by an intellectual property portfolio that covers Vascular Endothelial Growth Factors (VEGF) C and D, along with VEGF Receptor-3. This proprietary foundation targets diseases stemming from abnormal blood and lymphatic vessel growth or vascular leakage. The company's primary therapeutic candidate, OPT 302, is a soluble form of VEGFR-3 currently undergoing clinical evaluation. This novel agent is being developed for treating wet neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Furthermore, OPT 302 is designated as a pioneering VEGF C/D inhibitor, designed for administration alongside VEGF A inhibitors to manage wet neovascular AMD and other retinal diseases. Founded in 1984, the company officially changed its name from Circadian Technologies Limited to Opthea Limited in December 2015. Its corporate headquarters are located in South Yarra, Australia.